JPRN-UMIN000015949已完成2 期
A Prospective, Multi-center Phase II Trial on the Efficacy and Safety of Low-dose Erlotinib Monotherapy for Frail Patients with EGFR Mutation-positive, Non-small Cell Lung Cancer(TORG1425) - Low-dose Erlotinib for Frail Patients with EGFR Mutation-positive Non-Small Cell Lung Cancer(TORG1425)
PO Thoracic Oncology Research Group0 个研究点目标入组 80 人开始时间: 2014年12月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
An independent review committee confirmed a significant ORR of 60.0%(90% CI, 50.2%-69.2%). The disease control rate was 90.0%(90% CI, 82.7%-94.9%), median progression-free survival was 9.3 months (95%CI, 7.2-11.4 months), and median overall survival was 26.2 months (95%CI, 21.9-30.4 months).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) prior EGFR-TKI 2) active concomitant malignancy 3) concomitant brain metastasis require radiotherapy 4) interstitial pneumonia or lung fibrosis evident on CT 5) symptomatic ophthalmologic disease 6) patients having clinically important ophthalmic disorder 7) patients having clinically important neuropsychiatric disorder 8) pregnant or lactating women or those who declined contraception 9) patients judged to be not suitable by the attending physician
研究者
相似试验
已完成
2 期
The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)Diabetic Macular EdemaNCT05573100Curacle Co., Ltd.67
终止
2 期
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)Recurrent Glioblastoma Multiforme (GBM)NCT00290771Novartis231
已完成
3 期
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal VasculopathyMacular Polypoidal Choroidal Vasculopathy (PCV)NCT05666804Novartis Pharmaceuticals148
已完成
不适用
An Open Label, Single-Arm, Multi-center Phase II Study to Evaluate the safety and Efficacy of Herzuma® in Combination with Paclitaxel in HER2-positive Recurrent/Metastatic Urothelial CarcinomaKCT0003543Seoul National University Hospital27
已完成
2 期
CP-690-550 Ointment For Chronic Plaque PsoriasisPsoriasisNCT01246583Pfizer71